<Summary id="CDR0000258005" LegacyPDQID="1075" ReplacementFor="CDR0000062684"><SummaryMetaData><SummaryType>Treatment</SummaryType><SummaryAudience>Patients</SummaryAudience><SummaryLanguage>English</SummaryLanguage><SummaryDescription>Chronic lymphocytic leukemia (CLL) treatment can include observation, steroids, radiation therapy, chemotherapy, surgery, or targeted therapy. Learn more about the diagnosis, prognosis, and treatment of newly diagnosed or recurrent CLL in this expert-reviewed summary.</SummaryDescription><SummaryURL xref="https://www.cancer.gov/types/leukemia/patient/cll-treatment-pdq">Chronic Lymphocytic Leukemia (PDQ®): Treatment</SummaryURL><SummaryToggleURL xref="https://www.cancer.gov/types/leukemia/hp/cll-treatment-pdq">Chronic Lymphocytic Leukemia (PDQ®): Treatment</SummaryToggleURL><SummaryEditorialBoard ref="CDR0000028327">PDQ Adult Treatment Editorial Board</SummaryEditorialBoard><MainTopics><TermRef ref="CDR0000037765">chronic lymphocytic leukemia</TermRef></MainTopics><SummaryAbstract><Para id="_186">This PDQ cancer information summary has current information about the treatment of chronic lymphocytic leukemia. It is meant to inform and help patients, families, and caregivers. It does not give formal guidelines or recommendations for making decisions about health care.</Para><Para id="_187">Editorial Boards write the PDQ cancer information summaries and keep them up to date. These Boards are made up of experts in cancer treatment and other specialties related to cancer. The summaries are reviewed regularly and changes are made when there is new information. The date on each summary ("Date Last Modified") is the date of the most recent change. The information in this patient summary was taken from the health professional version, which is reviewed regularly and updated as needed, by the PDQ Adult Treatment Editorial Board.</Para></SummaryAbstract><SummaryKeyWords><SummaryKeyWord>chronic lymphocytic leukemia</SummaryKeyWord></SummaryKeyWords></SummaryMetaData><SummaryTitle>Chronic Lymphocytic Leukemia Treatment (PDQ®)–Patient Version</SummaryTitle><AltTitle TitleType="Browser">Chronic Lymphocytic Leukemia Treatment</AltTitle><AltTitle TitleType="CancerTypeHomePage">Chronic Lymphocytic Leukemia Treatment </AltTitle><SummarySection id="_1"><Title>General Information About Chronic Lymphocytic Leukemia</Title><SummarySection id="_2"><SectMetaData><SectionType>Cancer description</SectionType><SectionType>Organ description</SectionType></SectMetaData><KeyPoint id="_3">Chronic lymphocytic leukemia (CLL) is a type of cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell).</KeyPoint><Para id="_116"> CLL is a <GlossaryTermRef href="CDR0000045333" dictionary="Cancer.gov" audience="Patient">cancer</GlossaryTermRef> of the <GlossaryTermRef href="CDR0000270735" dictionary="Cancer.gov" audience="Patient">blood</GlossaryTermRef> and <GlossaryTermRef href="CDR0000045622" dictionary="Cancer.gov" audience="Patient">bone marrow</GlossaryTermRef> that usually gets worse slowly.  CLL is one of the most common types of <GlossaryTermRef href="CDR0000045343" dictionary="Cancer.gov" audience="Patient">leukemia</GlossaryTermRef> in adults.  It often occurs during or after middle age; it  rarely occurs in children.</Para><MediaLink ref="CDR0000755927" type="image/jpeg" alt="Anatomy of the bone; drawing shows spongy bone, red marrow, and yellow marrow. A cross section of the bone shows compact bone and blood vessels in the bone marrow. Also shown are red blood cells, white blood cells, platelets, and a blood stem cell." language="en" placement="image-center" id="_182"><Caption language="en">Anatomy of the bone. The bone is made up of compact bone, spongy bone, and bone marrow. Compact bone makes up the outer layer of the bone. Spongy bone is found mostly at the ends of bones and contains red marrow. Bone marrow is found in the center of most bones and has many blood vessels. There are two types of bone marrow: red and yellow. Red marrow contains blood stem cells that can become red blood cells, white blood cells, or platelets. Yellow marrow is made mostly of fat.</Caption></MediaLink></SummarySection><SummarySection id="_172"><SectMetaData><SectionType>Cancer description</SectionType></SectMetaData><KeyPoint id="_173">Leukemia may affect red blood cells, white blood cells, and platelets.</KeyPoint><Para id="_174">Normally, the bone marrow makes <GlossaryTermRef href="CDR0000765906" dictionary="Cancer.gov" audience="Patient">blood stem cells</GlossaryTermRef> (immature cells) that      become mature blood cells over time. A blood stem cell may become a <GlossaryTermRef href="CDR0000046279" dictionary="Cancer.gov" audience="Patient">myeloid</GlossaryTermRef> <GlossaryTermRef href="CDR0000046598" dictionary="Cancer.gov" audience="Patient">stem cell</GlossaryTermRef> or a <GlossaryTermRef href="CDR0000046298" dictionary="Cancer.gov" audience="Patient">lymphoid</GlossaryTermRef> stem cell.</Para><Para id="_175">A myeloid stem cell becomes one of three types of mature blood cells:</Para><ItemizedList id="_176" Style="bullet"><ListItem><GlossaryTermRef href="CDR0000046124" dictionary="Cancer.gov" audience="Patient">Red blood cells</GlossaryTermRef> that carry <GlossaryTermRef href="CDR0000538149" dictionary="Cancer.gov" audience="Patient">oxygen</GlossaryTermRef> and other substances to all tissues of the
			 body.</ListItem> 
		  <ListItem><GlossaryTermRef href="CDR0000046374" dictionary="Cancer.gov" audience="Patient">Granulocytes</GlossaryTermRef>, which are <GlossaryTermRef href="CDR0000045993" dictionary="Cancer.gov" audience="Patient">white blood cells</GlossaryTermRef> that help fight <GlossaryTermRef href="CDR0000045364" dictionary="Cancer.gov" audience="Patient">infection</GlossaryTermRef> and disease.</ListItem> 
		  <ListItem><GlossaryTermRef href="CDR0000045840" dictionary="Cancer.gov" audience="Patient">Platelets</GlossaryTermRef> that form <GlossaryTermRef href="CDR0000476017" dictionary="Cancer.gov" audience="Patient">blood clots</GlossaryTermRef> to stop bleeding.</ListItem></ItemizedList><Para id="_177">A lymphoid stem cell becomes a <GlossaryTermRef href="CDR0000302475" dictionary="Cancer.gov" audience="Patient">lymphoblast</GlossaryTermRef> cell and then one of three types of <GlossaryTermRef href="CDR0000045765" dictionary="Cancer.gov" audience="Patient">lymphocytes</GlossaryTermRef> (white blood cells):</Para><ItemizedList id="_178" Style="bullet"><ListItem><GlossaryTermRef href="CDR0000044953" dictionary="Cancer.gov" audience="Patient">B lymphocytes</GlossaryTermRef> that make <GlossaryTermRef href="CDR0000044918" dictionary="Cancer.gov" audience="Patient">antibodies</GlossaryTermRef> to help fight infection.</ListItem><ListItem><GlossaryTermRef href="CDR0000044928" dictionary="Cancer.gov" audience="Patient">T lymphocytes</GlossaryTermRef> that help B lymphocytes make the antibodies that help fight infection.</ListItem><ListItem><GlossaryTermRef href="CDR0000044062" dictionary="Cancer.gov" audience="Patient">Natural killer cells</GlossaryTermRef> that attack cancer cells and <GlossaryTermRef href="CDR0000045941" dictionary="Cancer.gov" audience="Patient">viruses</GlossaryTermRef>.</ListItem></ItemizedList><MediaLink ref="CDR0000526538" type="image/jpeg" alt="Blood cell development; drawing shows the steps a blood stem cell goes through to become a red blood cell, platelet, or white blood cell. A myeloid stem cell becomes a red blood cell, a platelet, or a myeloblast, which then becomes a granulocyte (the types of granulocytes are eosinophils, basophils, and neutrophils). A lymphoid stem cell becomes a lymphoblast and then becomes a B-lymphocyte, T-lymphocyte, or natural killer cell." language="en" placement="image-center" id="_153"><Caption language="en">Blood cell development. A blood stem cell goes through several steps to become a red blood cell, platelet, or white blood cell. </Caption></MediaLink><Para id="_179">In CLL, too many blood stem cells become abnormal lymphocytes.  The abnormal lymphocytes may also be called <GlossaryTermRef href="CDR0000804071" dictionary="Cancer.gov" audience="Patient">leukemia cells</GlossaryTermRef>.  These leukemia cells are not able to fight infection very well.  Also, as the number of leukemia cells increases in the blood and bone marrow, there is less room for healthy white blood cells, red blood cells, and platelets.  This may lead to infection, <GlossaryTermRef href="CDR0000045360" dictionary="Cancer.gov" audience="Patient">anemia</GlossaryTermRef>, and easy bleeding.</Para></SummarySection><SummarySection id="_13"><SectMetaData><SectionType>Symptoms</SectionType></SectMetaData><KeyPoint id="_14">Signs and  symptoms of CLL include swollen lymph nodes and feeling tired.</KeyPoint><Para id="_15">In the beginning, CLL does not cause any <GlossaryTermRef href="CDR0000750109" dictionary="Cancer.gov" audience="Patient">signs</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045022" dictionary="Cancer.gov" audience="Patient">symptoms</GlossaryTermRef> and may be found during a routine <GlossaryTermRef href="CDR0000688783" dictionary="Cancer.gov" audience="Patient">blood test</GlossaryTermRef>. Later, signs and  symptoms may occur. Check with your doctor if you have:</Para><ItemizedList id="_16" Style="bullet"> 
		   
		  <ListItem>Painless swelling of the <GlossaryTermRef href="CDR0000045762" dictionary="Cancer.gov" audience="Patient">lymph nodes</GlossaryTermRef> in the neck, underarm, <GlossaryTermRef href="CDR0000046604" dictionary="Cancer.gov" audience="Patient">stomach</GlossaryTermRef>, or <GlossaryTermRef href="CDR0000046375" dictionary="Cancer.gov" audience="Patient">groin</GlossaryTermRef>.</ListItem><ListItem>Weakness or feeling tired.</ListItem> 
		  <ListItem>Pain or a feeling of fullness below the ribs.</ListItem><ListItem>Fever and infection.</ListItem><ListItem>Easy bruising or bleeding.</ListItem><ListItem>Petechiae (flat, pinpoint, dark-red spots under the skin caused by bleeding).
</ListItem><ListItem>Weight loss for no known reason.</ListItem> 
		 
		  <ListItem><GlossaryTermRef href="CDR0000801579" dictionary="Cancer.gov" audience="Patient">Drenching night sweats</GlossaryTermRef>.</ListItem></ItemizedList></SummarySection><SummarySection id="_17"><SectMetaData><SectionType>Diagnostic tests</SectionType></SectMetaData><KeyPoint id="_18">Tests that examine the blood are used to diagnose CLL.</KeyPoint><Para id="_134">In addition to asking about your <GlossaryTermRef href="CDR0000642019" dictionary="Cancer.gov" audience="Patient">personal</GlossaryTermRef> and <GlossaryTermRef href="CDR0000642015" dictionary="Cancer.gov" audience="Patient">family health history</GlossaryTermRef> and doing a <GlossaryTermRef href="CDR0000270871" dictionary="Cancer.gov" audience="Patient">physical exam</GlossaryTermRef>, your doctor may perform the following tests and procedures:</Para><ItemizedList id="_19" Style="bullet"> 
		  
		  <ListItem><Strong><GlossaryTermRef href="CDR0000729979" dictionary="Cancer.gov" audience="Patient">Complete blood
			 count (CBC) with differential</GlossaryTermRef></Strong>: A procedure in which a sample of blood is drawn and
			 checked for: 
			 <ItemizedList id="_20" Style="dash"> 
				 
			 <ListItem> 
The number of red blood cells and platelets.</ListItem><ListItem>The number and type of white blood cells.</ListItem><ListItem>The amount of <GlossaryTermRef href="CDR0000045108" dictionary="Cancer.gov" audience="Patient">hemoglobin</GlossaryTermRef> (the <GlossaryTermRef href="CDR0000046092" dictionary="Cancer.gov" audience="Patient">protein</GlossaryTermRef> that carries oxygen) in the red blood cells.</ListItem><ListItem>The portion of the blood sample made up of red blood cells.

</ListItem></ItemizedList><MediaLink ref="CDR0000526546" type="image/jpeg" alt="Complete blood count (CBC); left panel shows blood being drawn from a vein on the inside of the elbow using a tube attached to a syringe; right panel shows a laboratory test tube with blood cells separated into layers: plasma, white blood cells, platelets, and red blood cells." language="en" placement="image-center" id="_148"><Caption language="en">Complete blood count (CBC). Blood is collected by inserting a needle into a vein and allowing the blood to flow into a tube. The blood sample is sent to the laboratory and the red blood cells, white blood cells, and platelets are counted.  The CBC is used to test for, diagnose, and monitor many different conditions.</Caption></MediaLink></ListItem> 
		  <ListItem><Strong><GlossaryTermRef href="CDR0000304685" dictionary="Cancer.gov" audience="Patient">Blood chemistry studies</GlossaryTermRef></Strong>: A procedure in which a blood sample is checked to measure the amounts of certain substances released into the blood by organs and tissues in the body. An unusual (higher or lower than normal) amount of a substance can be a sign of disease.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000354462" dictionary="Cancer.gov" audience="Patient">Lactate dehydrogenase</GlossaryTermRef> testing</Strong>: A <GlossaryTermRef href="CDR0000046590" dictionary="Cancer.gov" audience="Patient">laboratory test</GlossaryTermRef> for one of a group of <GlossaryTermRef href="CDR0000046081" dictionary="Cancer.gov" audience="Patient">enzymes</GlossaryTermRef> found in the blood and other body tissues and involved in energy production in cells. An increased amount of lactate dehydrogenase  in the blood may be a sign of tissue damage and some types of cancer or other diseases.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000411372" dictionary="Cancer.gov" audience="Patient">Beta-2-microglobulin</GlossaryTermRef> testing</Strong>: A laboratory test for beta-2-microglobulin, a small protein normally found on the surface of many cells, including lymphocytes, and in small amounts in the blood and urine. An increased amount in the blood or urine may be a sign of certain diseases, including some types of cancer, such as <GlossaryTermRef href="CDR0000045793" dictionary="Cancer.gov" audience="Patient">multiple myeloma</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045368" dictionary="Cancer.gov" audience="Patient">lymphoma</GlossaryTermRef>. </ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000335066" dictionary="Cancer.gov" audience="Patient">Flow cytometry</GlossaryTermRef></Strong>: A laboratory test that measures the number of cells in a sample, the percentage of live cells in a sample, and certain characteristics of the cells, such as size, shape, and the presence of tumor (or other) <GlossaryTermRef href="CDR0000046636" dictionary="Cancer.gov" audience="Patient">markers</GlossaryTermRef> on the cell surface. The cells from a sample of a patient’s blood, bone marrow, or other tissue are stained with a fluorescent dye, placed in a fluid, and then passed one at a time through a beam of light. The test results are based on how the cells that were stained with the fluorescent dye react to the beam of light. This test is used to help diagnose and manage certain types of cancers, such as leukemia and <GlossaryTermRef href="CDR0000045368" dictionary="Cancer.gov" audience="Patient">lymphoma</GlossaryTermRef>.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000460228" dictionary="Cancer.gov" audience="Patient">FISH</GlossaryTermRef> (fluorescence in situ hybridization)</Strong>: A laboratory test used to look at and count <GlossaryTermRef href="CDR0000045693" dictionary="Cancer.gov" audience="Patient">genes</GlossaryTermRef> or <GlossaryTermRef href="CDR0000046470" dictionary="Cancer.gov" audience="Patient">chromosomes</GlossaryTermRef> in cells and tissues. Pieces of <GlossaryTermRef href="CDR0000045671" dictionary="Cancer.gov" audience="Patient">DNA</GlossaryTermRef> that contain fluorescent dyes are made in the laboratory and added to a sample of a patient’s cells or tissues. When these dyed pieces of DNA attach to certain genes or areas of chromosomes in the sample, they light up when viewed under a fluorescent microscope. The FISH test is used to help diagnose cancer and help plan treatment.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000046128" dictionary="Cancer.gov" audience="Patient">Genetic testing</GlossaryTermRef></Strong>: A laboratory test in which cells or tissue are analyzed to look for changes in the <GeneName><GlossaryTermRef href="CDR0000796656" dictionary="Cancer.gov" audience="Patient">TP53</GlossaryTermRef></GeneName> or <GeneName>IGH</GeneName> gene. These changes may be helpful to determine the patient's <GlossaryTermRef href="CDR0000045849" dictionary="Cancer.gov" audience="Patient">prognosis</GlossaryTermRef>.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000044088" dictionary="Cancer.gov" audience="Patient">Serum</GlossaryTermRef> <GlossaryTermRef href="CDR0000045725" dictionary="Cancer.gov" audience="Patient">immunoglobulin</GlossaryTermRef> testing</Strong>: A laboratory test that measures specific types of immunoglobulins (antibodies) in the blood. This may help diagnose cancer or find out how well treatment is working or if cancer has come back.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000046146" dictionary="Cancer.gov" audience="Patient">Hepatitis B virus</GlossaryTermRef> and <GlossaryTermRef href="CDR0000044139" dictionary="Cancer.gov" audience="Patient">hepatitis C virus</GlossaryTermRef> testing</Strong>:  A test to check for hepatitis B or hepatitis C virus in the blood. Infection with one of these viruses   causes  hepatitis (<GlossaryTermRef href="CDR0000044042" dictionary="Cancer.gov" audience="Patient">inflammation</GlossaryTermRef> of the <GlossaryTermRef href="CDR0000046312" dictionary="Cancer.gov" audience="Patient">liver</GlossaryTermRef>).</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000759626" dictionary="Cancer.gov" audience="Patient">HIV testing</GlossaryTermRef></Strong>: A test to check for HIV infection. HIV is the virus that causes AIDS. The most common type of HIV test is called the <GlossaryTermRef href="CDR0000762531" dictionary="Cancer.gov" audience="Patient">HIV antibody test</GlossaryTermRef>, which checks for antibodies against HIV in a sample of blood, urine, or fluid from the mouth.</ListItem> 
		  
		   
		</ItemizedList></SummarySection><SummarySection id="_21"><SectMetaData><SectionType>Prognostic factors</SectionType></SectMetaData><KeyPoint id="_22">Certain factors affect prognosis (chance
		  of recovery) and treatment options.</KeyPoint><Para id="_141">The <GlossaryTermRef href="CDR0000045849" dictionary="Cancer.gov" audience="Patient">prognosis</GlossaryTermRef> depends on:</Para><ItemizedList id="_137" Style="bullet"><ListItem>Whether there are certain gene changes, such as in <GeneName>TP53</GeneName> or <GeneName>IGH</GeneName>.</ListItem><ListItem>Whether lymphocytes have spread throughout the bone marrow.</ListItem><ListItem>Whether the red blood cell and platelet counts are low.</ListItem><ListItem>Whether the white blood cell count is increasing quickly.</ListItem><ListItem>The  <GlossaryTermRef href="CDR0000045885" dictionary="Cancer.gov" audience="Patient">stage</GlossaryTermRef> of the cancer.</ListItem><ListItem>The results of certain blood tests, such as the <GlossaryTermRef href="CDR0000411372" dictionary="Cancer.gov" audience="Patient">beta-2 microglobulin</GlossaryTermRef> and <GlossaryTermRef href="CDR0000354462" dictionary="Cancer.gov" audience="Patient">lactate dehydrogenase</GlossaryTermRef> tests.</ListItem><ListItem>The patient's age and general health.</ListItem><ListItem>How quickly and how low the leukemia cell count drops during treatment.</ListItem><ListItem>Whether the CLL gets better with treatment or has recurred (come back).</ListItem><ListItem>Whether the CLL <GlossaryTermRef href="CDR0000044078" dictionary="Cancer.gov" audience="Patient">progresses</GlossaryTermRef> to lymphoma or becomes <GlossaryTermRef href="CDR0000045380" dictionary="Cancer.gov" audience="Patient">prolymphocytic leukemia</GlossaryTermRef>.</ListItem><ListItem>Whether the patient gets another type of cancer after being diagnosed with CLL.</ListItem></ItemizedList><Para id="_140">Treatment options depend on:</Para><ItemizedList id="_135" Style="bullet"><ListItem>The red blood cell, white blood cell, and platelet blood counts.</ListItem><ListItem>Whether the <GlossaryTermRef href="CDR0000046312" dictionary="Cancer.gov" audience="Patient">liver</GlossaryTermRef>, <GlossaryTermRef href="CDR0000046593" dictionary="Cancer.gov" audience="Patient">spleen</GlossaryTermRef>, or lymph nodes are larger than normal.</ListItem><ListItem>The age and health of the patient at the time of diagnosis.</ListItem><ListItem>Whether there are signs or symptoms, such as fever, chills, or weight loss.</ListItem><ListItem>The <GlossaryTermRef href="CDR0000044085" dictionary="Cancer.gov" audience="Patient">response</GlossaryTermRef> to initial treatment.</ListItem><ListItem>Whether the CLL has <GlossaryTermRef href="CDR0000046556" dictionary="Cancer.gov" audience="Patient">recurred</GlossaryTermRef> (come back).</ListItem></ItemizedList></SummarySection></SummarySection><SummarySection id="_24"><Title>Stage Information for Chronic Lymphocytic Leukemia</Title><SummarySection id="_25"><SectMetaData><SectionType>Diagnostic tests</SectionType></SectMetaData><KeyPoint id="_26">After chronic lymphocytic leukemia (CLL) has been diagnosed, tests
		  are done to find out  whether the cancer has spread.</KeyPoint><Para id="_27">Staging is the process used to find out how far the cancer has spread. In <GlossaryTermRef href="CDR0000346545" dictionary="Cancer.gov" audience="Patient">CLL</GlossaryTermRef>, the <GlossaryTermRef href="CDR0000804071" dictionary="Cancer.gov" audience="Patient">leukemia cells</GlossaryTermRef> may spread from the blood and <GlossaryTermRef href="CDR0000045622" dictionary="Cancer.gov" audience="Patient">bone marrow</GlossaryTermRef> to other parts of the body, such as the <GlossaryTermRef href="CDR0000045762" dictionary="Cancer.gov" audience="Patient">lymph nodes</GlossaryTermRef>, <GlossaryTermRef href="CDR0000046312" dictionary="Cancer.gov" audience="Patient">liver</GlossaryTermRef>, and <GlossaryTermRef href="CDR0000046593" dictionary="Cancer.gov" audience="Patient">spleen</GlossaryTermRef>. It is important to know whether the leukemia cells have spread in order to plan the best treatment.</Para><Para id="_216">The following tests may be used to find out how far the cancer has spread:</Para><ItemizedList id="_28" Style="bullet"> 
		   
		  
		  <ListItem><Strong><GlossaryTermRef href="CDR0000304687" dictionary="Cancer.gov" audience="Patient">Chest x-ray</GlossaryTermRef></Strong>: An <GlossaryTermRef href="CDR0000045944" dictionary="Cancer.gov" audience="Patient">x-ray</GlossaryTermRef> of the organs and bones inside the chest.  An x-ray is a type of energy beam that can go through the body and onto film, making a picture of areas inside the body, such as the <GlossaryTermRef href="CDR0000045762" dictionary="Cancer.gov" audience="Patient">lymph nodes</GlossaryTermRef>.</ListItem> 
		<ListItem><Strong><GlossaryTermRef href="CDR0000046033" dictionary="Cancer.gov" audience="Patient">CT scan</GlossaryTermRef> (CAT scan)</Strong>: A procedure that makes a series of detailed pictures of areas inside the body, such as the neck, chest, <GlossaryTermRef href="CDR0000045070" dictionary="Cancer.gov" audience="Patient">abdomen</GlossaryTermRef>, <GlossaryTermRef href="CDR0000046246" dictionary="Cancer.gov" audience="Patient">pelvis</GlossaryTermRef>, and lymph nodes, taken from different angles. The pictures are made by a computer linked to an x-ray machine. A dye may be <GlossaryTermRef href="CDR0000044678" dictionary="Cancer.gov" audience="Patient">injected</GlossaryTermRef> into a vein or swallowed to help the organs or tissues show up more clearly. This test is used in patients with many swollen lymph nodes throughout the body. This procedure is also called computed tomography, computerized tomography, or computerized axial tomography. If a PET-CT scan is not available, a CT scan alone may be done.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000742485" dictionary="Cancer.gov" audience="Patient">PET-CT scan</GlossaryTermRef></Strong>: A procedure that combines the pictures from a positron emission tomography (PET) scan and a <GlossaryTermRef href="CDR0000045560" dictionary="Cancer.gov" audience="Patient">computed tomography (CT) scan</GlossaryTermRef>. The PET and CT scans are done at the same time on the same machine. The pictures from both scans are combined to make a more detailed picture than either test would make by itself. A PET scan is a procedure to find <GlossaryTermRef href="CDR0000045772" dictionary="Cancer.gov" audience="Patient">malignant</GlossaryTermRef> tumor cells in the body. A small amount of <GlossaryTermRef href="CDR0000774386" dictionary="Cancer.gov" audience="Patient">radioactive glucose</GlossaryTermRef> (sugar) is injected into a vein. The PET <GlossaryTermRef href="CDR0000386220" dictionary="Cancer.gov" audience="Patient">scanner</GlossaryTermRef> rotates around the body and makes a picture of where glucose is being used in the body. Malignant tumor cells show up brighter in the picture because they are more active and take up more glucose than normal cells do. This test is done in patients with fever, <GlossaryTermRef href="CDR0000801579" dictionary="Cancer.gov" audience="Patient">drenching night sweats</GlossaryTermRef>, weight loss, or fast-growing lymph nodes to check whether CLL has become an <GlossaryTermRef href="CDR0000045588" dictionary="Cancer.gov" audience="Patient">aggressive</GlossaryTermRef> form of lymphoma.</ListItem></ItemizedList></SummarySection><SummarySection id="_29"><SectMetaData><SectionType>Classification by stage</SectionType></SectMetaData><KeyPoint id="_30">The following stages are used for CLL:</KeyPoint><SummarySection id="_31"><KeyPoint id="_32">Stage 0</KeyPoint><Para id="_33">In <GlossaryTermRef href="CDR0000044847" dictionary="Cancer.gov" audience="Patient">stage 0 CLL</GlossaryTermRef>, there are too many
			 <GlossaryTermRef href="CDR0000045765" dictionary="Cancer.gov" audience="Patient">lymphocytes</GlossaryTermRef> in the blood, but there are no other signs or <GlossaryTermRef href="CDR0000045022" dictionary="Cancer.gov" audience="Patient">symptoms</GlossaryTermRef> of <GlossaryTermRef href="CDR0000045343" dictionary="Cancer.gov" audience="Patient">leukemia</GlossaryTermRef>.
			 Stage 0 CLL is indolent (slow-growing).</Para></SummarySection><SummarySection id="_34"><KeyPoint id="_35">Stage I</KeyPoint><Para id="_36">In <GlossaryTermRef href="CDR0000045057" dictionary="Cancer.gov" audience="Patient">stage I CLL</GlossaryTermRef>, there
			 are too many <GlossaryTermRef href="CDR0000045765" dictionary="Cancer.gov" audience="Patient">lymphocytes</GlossaryTermRef> in the blood, and the <GlossaryTermRef href="CDR0000045762" dictionary="Cancer.gov" audience="Patient">lymph nodes</GlossaryTermRef> are larger than normal. </Para></SummarySection><SummarySection id="_37"><KeyPoint id="_38">Stage II</KeyPoint><Para id="_39">In <GlossaryTermRef href="CDR0000045059" dictionary="Cancer.gov" audience="Patient">stage II CLL</GlossaryTermRef>, there
			 are too many <GlossaryTermRef href="CDR0000045765" dictionary="Cancer.gov" audience="Patient">lymphocytes</GlossaryTermRef> in the blood,   the <GlossaryTermRef href="CDR0000046312" dictionary="Cancer.gov" audience="Patient">liver</GlossaryTermRef> or <GlossaryTermRef href="CDR0000046593" dictionary="Cancer.gov" audience="Patient">spleen</GlossaryTermRef>
			 is larger than normal, and the <GlossaryTermRef href="CDR0000045762" dictionary="Cancer.gov" audience="Patient">lymph nodes</GlossaryTermRef> may be larger than normal.</Para></SummarySection><SummarySection id="_40"><KeyPoint id="_41">Stage III</KeyPoint><Para id="_42">In <GlossaryTermRef href="CDR0000045061" dictionary="Cancer.gov" audience="Patient">stage III CLL</GlossaryTermRef>,
			 there are too many <GlossaryTermRef href="CDR0000045765" dictionary="Cancer.gov" audience="Patient">lymphocytes</GlossaryTermRef> in the blood, and there are too few <GlossaryTermRef href="CDR0000046124" dictionary="Cancer.gov" audience="Patient">red blood
			 cells</GlossaryTermRef>. The <GlossaryTermRef href="CDR0000045762" dictionary="Cancer.gov" audience="Patient">lymph nodes</GlossaryTermRef>, <GlossaryTermRef href="CDR0000046312" dictionary="Cancer.gov" audience="Patient">liver</GlossaryTermRef>, or <GlossaryTermRef href="CDR0000046593" dictionary="Cancer.gov" audience="Patient">spleen</GlossaryTermRef> may be larger than normal.</Para></SummarySection><SummarySection id="_197"><KeyPoint id="_198">Stage IV</KeyPoint><Para id="_199">In <GlossaryTermRef href="CDR0000045062" dictionary="Cancer.gov" audience="Patient">stage IV CLL</GlossaryTermRef>, there
			 are too many <GlossaryTermRef href="CDR0000045765" dictionary="Cancer.gov" audience="Patient">lymphocytes</GlossaryTermRef> in the blood and too few <GlossaryTermRef href="CDR0000045840" dictionary="Cancer.gov" audience="Patient">platelets</GlossaryTermRef>. The <GlossaryTermRef href="CDR0000045762" dictionary="Cancer.gov" audience="Patient">lymph nodes</GlossaryTermRef>, <GlossaryTermRef href="CDR0000046312" dictionary="Cancer.gov" audience="Patient">liver</GlossaryTermRef>, or <GlossaryTermRef href="CDR0000046593" dictionary="Cancer.gov" audience="Patient">spleen</GlossaryTermRef> may be larger than normal,
			 or there may be too few <GlossaryTermRef href="CDR0000046124" dictionary="Cancer.gov" audience="Patient">red blood cells</GlossaryTermRef>.</Para></SummarySection></SummarySection><SummarySection id="_218"><KeyPoint id="_219">CLL is described as asymptomatic, symptomatic or progressive, recurrent, or refractory.</KeyPoint><ItemizedList id="_220" Style="bullet"><ListItem><GlossaryTermRef href="CDR0000046520" dictionary="Cancer.gov" audience="Patient">Asymptomatic</GlossaryTermRef> CLL: The leukemia causes no or few <GlossaryTermRef href="CDR0000045022" dictionary="Cancer.gov" audience="Patient">symptoms</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000044090" dictionary="Cancer.gov" audience="Patient">Symptomatic</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045850" dictionary="Cancer.gov" audience="Patient">progressive</GlossaryTermRef> CLL: The leukemia has caused significant changes to blood counts or other serious symptoms.</ListItem><ListItem><GlossaryTermRef href="CDR0000045862" dictionary="Cancer.gov" audience="Patient">Recurrent</GlossaryTermRef> CLL: The leukemia has recurred (come back) after a period of time in which the cancer could not be detected.</ListItem><ListItem><GlossaryTermRef href="CDR0000045863" dictionary="Cancer.gov" audience="Patient">Refractory</GlossaryTermRef> CLL: The leukemia does not get better with treatment.</ListItem></ItemizedList></SummarySection></SummarySection><SummarySection id="_48"><Title>Treatment Option Overview</Title><SummarySection id="_49"><SectMetaData><SectionType>Standard treatment</SectionType></SectMetaData><KeyPoint id="_50">There are different types of treatment for patients with
		  chronic lymphocytic leukemia (CLL).</KeyPoint><Para id="_51">Different types of treatment are available for patients with CLL.
		  Some treatments are <GlossaryTermRef href="CDR0000044930" dictionary="Cancer.gov" audience="Patient">standard</GlossaryTermRef> (the currently used treatment), and some are being
		  tested in <GlossaryTermRef href="CDR0000045961" dictionary="Cancer.gov" audience="Patient">clinical trials</GlossaryTermRef>. A treatment clinical trial is a <GlossaryTermRef href="CDR0000651211" dictionary="Cancer.gov" audience="Patient">research study</GlossaryTermRef> meant to help improve
		  current treatments or obtain information on new treatments for patients with
		  cancer. When clinical trials show that a new treatment is better than the
		  standard treatment, the new
		  treatment may become the standard treatment.    Patients may want to think about taking part in a clinical trial. Some clinical trials are open only to patients who have not started treatment.</Para></SummarySection><SummarySection id="_241"><SectMetaData><SectionType>Standard treatment</SectionType></SectMetaData><KeyPoint id="_242">The following types of treatment are used:</KeyPoint><SummarySection id="_243"><KeyPoint id="_244">Watchful waiting</KeyPoint><Para id="_245">Watchful waiting
			 is closely monitoring a patient's condition without giving any treatment until <GlossaryTermRef href="CDR0000750109" dictionary="Cancer.gov" audience="Patient">signs</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045022" dictionary="Cancer.gov" audience="Patient">symptoms</GlossaryTermRef> appear or change. This is also called observation. Watchful waiting is used to treat <GlossaryTermRef href="CDR0000046520" dictionary="Cancer.gov" audience="Patient">asymptomatic</GlossaryTermRef> and <GlossaryTermRef href="CDR0000044090" dictionary="Cancer.gov" audience="Patient">symptomatic</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045850" dictionary="Cancer.gov" audience="Patient">progressive</GlossaryTermRef> <GlossaryTermRef href="CDR0000346545" dictionary="Cancer.gov" audience="Patient">CLL</GlossaryTermRef>.</Para></SummarySection><SummarySection id="_246"><KeyPoint id="_247">Targeted therapy</KeyPoint><Para id="_248"><GlossaryTermRef href="CDR0000270742" dictionary="Cancer.gov" audience="Patient">Targeted therapy</GlossaryTermRef> is a type of treatment that uses drugs or other substances to identify and attack specific cancer cells. Different types of targeted therapy are used to treat CLL:</Para><ItemizedList id="_249" Style="bullet" Compact="No"><ListItem><Strong><GlossaryTermRef href="CDR0000044833" dictionary="Cancer.gov" audience="Patient">Tyrosine kinase inhibitor</GlossaryTermRef> (TKI) therapy</Strong>: This treatment blocks the <GlossaryTermRef href="CDR0000046081" dictionary="Cancer.gov" audience="Patient">enzyme</GlossaryTermRef>, tyrosine kinase, that causes <GlossaryTermRef href="CDR0000046598" dictionary="Cancer.gov" audience="Patient">stem cells</GlossaryTermRef> to develop into more <GlossaryTermRef href="CDR0000045993" dictionary="Cancer.gov" audience="Patient">white blood cells</GlossaryTermRef> than the body needs. <GlossaryTermRef href="CDR0000754851" dictionary="Cancer.gov" audience="Patient">Ibrutinib</GlossaryTermRef>, <GlossaryTermRef href="CDR0000791334" dictionary="Cancer.gov" audience="Patient">acalabrutinib</GlossaryTermRef>, <GlossaryTermRef href="CDR0000799967" dictionary="Cancer.gov" audience="Patient">zanubrutinib</GlossaryTermRef>, and <GlossaryTermRef href="CDR0000795008" dictionary="Cancer.gov" audience="Patient">duvelisib</GlossaryTermRef> are TKIs used to treat symptomatic or progressive, <GlossaryTermRef href="CDR0000045862" dictionary="Cancer.gov" audience="Patient">recurrent</GlossaryTermRef>, or <GlossaryTermRef href="CDR0000045863" dictionary="Cancer.gov" audience="Patient">refractory</GlossaryTermRef> CLL.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000613897" dictionary="Cancer.gov" audience="Patient">BCL2</GlossaryTermRef> inhibitor therapy</Strong>: This treatment blocks a <GlossaryTermRef href="CDR0000046092" dictionary="Cancer.gov" audience="Patient">protein</GlossaryTermRef> called BCL2, which is found on some <GlossaryTermRef href="CDR0000804071" dictionary="Cancer.gov" audience="Patient">leukemia cells</GlossaryTermRef>. This may kill leukemia cells and make them more sensitive to other anticancer drugs. <GlossaryTermRef href="CDR0000780268" dictionary="Cancer.gov" audience="Patient">Venetoclax</GlossaryTermRef> is a type of BCL2 therapy used to treat symptomatic or progressive, recurrent, or refractory CLL.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000046066" dictionary="Cancer.gov" audience="Patient">Monoclonal antibody</GlossaryTermRef> therapy</Strong>: Monoclonal antibodies are <GlossaryTermRef href="CDR0000046356" dictionary="Cancer.gov" audience="Patient">immune system</GlossaryTermRef> proteins made in the laboratory to treat many diseases, including cancer. As a cancer treatment, these <GlossaryTermRef href="CDR0000044918" dictionary="Cancer.gov" audience="Patient">antibodies</GlossaryTermRef> can attach to a specific target on cancer cells or other cells that may help cancer cells grow.  The antibodies are able to then kill the cancer cells, block their growth, or keep them from spreading. Monoclonal antibodies are given by <GlossaryTermRef href="CDR0000045738" dictionary="Cancer.gov" audience="Patient">infusion</GlossaryTermRef>. They may be used alone or to carry drugs, toxins, or <GlossaryTermRef href="CDR0000046550" dictionary="Cancer.gov" audience="Patient">radioactive</GlossaryTermRef> material directly to cancer cells. <GlossaryTermRef href="CDR0000045525" dictionary="Cancer.gov" audience="Patient">Rituximab</GlossaryTermRef>, <GlossaryTermRef href="CDR0000537262" dictionary="Cancer.gov" audience="Patient">ofatumumab</GlossaryTermRef>, <GlossaryTermRef href="CDR0000754339" dictionary="Cancer.gov" audience="Patient">obinutuzumab</GlossaryTermRef>, and <GlossaryTermRef href="CDR0000044851" dictionary="Cancer.gov" audience="Patient">alemtuzumab</GlossaryTermRef> alone and in combination with chemotherapy are used  to treat symptomatic or progressive, recurrent, or refractory   CLL.<EmbeddedVideo id="_275" ref="CDR0000801837" hosting="youtube" unique_id="dxnjAc-rqz8" language="en" audience="Patients" template="Video75NoTitle"><VideoTitle>monoclonal antibodies: how monoclonal antibodies treat cancer</VideoTitle><Caption language="en">How do  monoclonal antibodies work to treat cancer? This video shows how monoclonal antibodies, such as trastuzumab, pembrolizumab, and rituximab, block molecules cancer cells need to grow, flag cancer cells for destruction by the body’s immune system, or deliver harmful substances to cancer cells. </Caption></EmbeddedVideo></ListItem></ItemizedList><Para id="_251">For more information, see <ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/drugs/leukemia#6">Drugs Approved for Chronic Lymphocytic Leukemia</ExternalRef>.</Para></SummarySection><SummarySection id="_252"><KeyPoint id="_253">Chemotherapy</KeyPoint><Para id="_254">Chemotherapy is a cancer treatment that uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.   When chemotherapy is taken by mouth or <GlossaryTermRef href="CDR0000044678" dictionary="Cancer.gov" audience="Patient">injected</GlossaryTermRef> into a vein or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body (systemic chemotherapy). Combination chemotherapy is treatment using more than one anticancer drug.</Para><Para id="_255">For more information, see <ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/drugs/leukemia#6">Drugs Approved for Chronic Lymphocytic Leukemia</ExternalRef>.</Para></SummarySection><SummarySection id="_256"><KeyPoint id="_257">Radiation therapy</KeyPoint><Para id="_258">Radiation therapy is a cancer treatment that uses high-energy <GlossaryTermRef href="CDR0000045944" dictionary="Cancer.gov" audience="Patient">x-rays</GlossaryTermRef> or other types of <GlossaryTermRef href="CDR0000045072" dictionary="Cancer.gov" audience="Patient">radiation</GlossaryTermRef> to kill cancer cells or keep them from growing. External radiation therapy uses a machine outside the body to send radiation toward the area of the body with cancer, such as a group of <GlossaryTermRef href="CDR0000045762" dictionary="Cancer.gov" audience="Patient">lymph nodes</GlossaryTermRef> or the <GlossaryTermRef href="CDR0000046593" dictionary="Cancer.gov" audience="Patient">spleen</GlossaryTermRef>. This treatment may be used to reduce pain related to a swollen spleen or lymph nodes.</Para></SummarySection><SummarySection id="_269"><KeyPoint id="_270">Immunotherapy</KeyPoint><Para id="_271"><GlossaryTermRef href="CDR0000045729" dictionary="Cancer.gov" audience="Patient">Immunotherapy</GlossaryTermRef> is a treatment that uses the patient's <GlossaryTermRef href="CDR0000046356" dictionary="Cancer.gov" audience="Patient">immune system</GlossaryTermRef> to fight cancer.  Substances made by the body or made in a laboratory are used to boost, direct, or restore the body's natural defenses against cancer.</Para><ItemizedList id="_272" Style="bullet"><ListItem><Strong><GlossaryTermRef href="CDR0000739791" dictionary="Cancer.gov" audience="Patient">Immunomodulating agent</GlossaryTermRef></Strong>: <GlossaryTermRef href="CDR0000393761" dictionary="Cancer.gov" audience="Patient">Lenalidomide</GlossaryTermRef> stimulates <GlossaryTermRef href="CDR0000044928" dictionary="Cancer.gov" audience="Patient">T cells</GlossaryTermRef> to kill leukemia cells. It may be used  alone or with <GlossaryTermRef href="CDR0000045525" dictionary="Cancer.gov" audience="Patient">rituximab</GlossaryTermRef> in patients with symptomatic or progressive, recurrent, or refractory  CLL.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000771302" dictionary="Cancer.gov" audience="Patient">CAR T-cell therapy</GlossaryTermRef></Strong>: This treatment changes the patient's <GlossaryTermRef href="CDR0000044928" dictionary="Cancer.gov" audience="Patient">T cells</GlossaryTermRef> (a type of immune system cell) so they will attack certain <GlossaryTermRef href="CDR0000046092" dictionary="Cancer.gov" audience="Patient">proteins</GlossaryTermRef> on the surface of cancer cells. T cells are taken from the patient and special <GlossaryTermRef href="CDR0000044958" dictionary="Cancer.gov" audience="Patient">receptors</GlossaryTermRef> are added to their surface in the laboratory. The changed cells are called <GlossaryTermRef href="CDR0000787969" dictionary="Cancer.gov" audience="Patient">chimeric antigen receptor</GlossaryTermRef> (CAR) T cells. The CAR T cells are grown in the laboratory and given to the patient by <GlossaryTermRef href="CDR0000045738" dictionary="Cancer.gov" audience="Patient">infusion</GlossaryTermRef>. The CAR T cells multiply in the patient's blood and attack cancer cells. CAR T-cell therapy is being studied in the treatment of recurrent or refractory CLL.<MediaLink ref="CDR0000774647" type="image/jpeg" alt="CAR T-cell therapy; drawing of blood being removed from a vein in a patient’s arm to get T cells. Also shown is a special receptor called a chimeric antigen receptor (CAR) being made in the laboratory; the gene for CAR is inserted into the T cells and then millions of CAR T cells are grown. Drawing also shows the CAR T cells being given to the patient by infusion and binding to antigens on the cancer cells and killing them." language="en" placement="image-center" id="_273"><Caption language="en">CAR T-cell therapy. A type of treatment in which a patient’s T cells (a type of immune cell) are changed in the laboratory so they will bind to cancer cells and kill them. Blood from a vein in the patient’s arm flows through a tube to an apheresis machine (not shown), which removes the white blood cells, including the T cells, and sends the rest of the blood back to the patient. Then, the gene for a special receptor called a chimeric antigen receptor (CAR) is inserted into the T cells in the laboratory. Millions of the CAR T cells are grown in the laboratory and then given to the patient by infusion. The CAR T cells are able to bind to an antigen on the cancer cells and kill them.</Caption></MediaLink></ListItem></ItemizedList></SummarySection><SummarySection id="_277"><KeyPoint id="_278">Chemotherapy with bone marrow or peripheral blood stem cell transplant</KeyPoint><Para id="_279">Chemotherapy is given to kill cancer cells. Healthy cells, including blood-forming cells, are destroyed by the cancer treatment. A <GlossaryTermRef href="CDR0000045263" dictionary="Cancer.gov" audience="Patient">bone marrow</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045828" dictionary="Cancer.gov" audience="Patient">peripheral blood stem cell</GlossaryTermRef> transplant are treatments to replace the blood-forming cells.  <GlossaryTermRef href="CDR0000046598" dictionary="Cancer.gov" audience="Patient">Stem cells</GlossaryTermRef> (immature blood cells) are removed from the blood or bone marrow of the patient or a <GlossaryTermRef href="CDR0000643010" dictionary="Cancer.gov" audience="Patient">donor</GlossaryTermRef> and are frozen and stored.  After the patient completes chemotherapy, the stored stem cells are thawed and given back to the patient through an infusion.  These reinfused stem cells grow into (and restore) the body's blood cells.</Para></SummarySection></SummarySection><SummarySection id="_82"><SectMetaData><SectionType>Treatment in clinical trials</SectionType></SectMetaData><KeyPoint id="_83">New types of treatment are being tested in clinical trials.</KeyPoint><Para id="_151">Information about  clinical trials is available from the
		  <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials">NCI website</ExternalRef>.</Para></SummarySection><SummarySection id="_192"><KeyPoint id="_193">Treatment for chronic lymphocytic leukemia may cause side effects.</KeyPoint><Para id="_192_md_73">For information about <GlossaryTermRef href="CDR0000046580" dictionary="Cancer.gov" audience="Patient">side effects</GlossaryTermRef> caused by treatment for cancer, visit our <ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/side-effects">Side Effects</ExternalRef> page.</Para></SummarySection><SummarySection id="_154"><KeyPoint id="_155">Patients may want to think about taking part in a clinical trial.</KeyPoint><Para id="_154_md_23">For some patients, taking part in a <GlossaryTermRef href="CDR0000045961" dictionary="Cancer.gov" audience="Patient">clinical trial</GlossaryTermRef> may be the best treatment choice. Clinical trials are part of the cancer research process. Clinical trials are done to find out if new cancer  treatments are safe and effective or better than the <GlossaryTermRef href="CDR0000044930" dictionary="Cancer.gov" audience="Patient">standard treatment</GlossaryTermRef>.</Para><Para id="_154_md_24">Many of today's standard treatments for cancer are based on earlier clinical trials. Patients who take part in a clinical trial may receive the standard treatment or be among the first  to receive a new treatment.</Para><Para id="_154_md_25">Patients who take part in clinical trials also help improve the way cancer will be treated in the future. Even when clinical trials do not lead to effective new treatments, they often answer important questions and help move research forward.</Para></SummarySection><SummarySection id="_156"><KeyPoint id="_157">Patients can enter clinical trials before, during, or after starting their cancer treatment.</KeyPoint><Para id="_156_md_29">Some clinical trials only include patients who have not yet received treatment. Other trials test treatments for patients whose cancer has not gotten better. There are also clinical trials that test new ways to stop cancer from recurring (coming back) or reduce the <GlossaryTermRef href="CDR0000046580" dictionary="Cancer.gov" audience="Patient">side effects</GlossaryTermRef> of cancer treatment.</Para><Para id="_156_md_30">Clinical trials are taking place in many parts of the country. Information about clinical trials supported by NCI can be found on NCI’s <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials-search">clinical trials search</ExternalRef> webpage. Clinical trials supported by other organizations can be found on the <ExternalRef xref="https://clinicaltrials.gov/">ClinicalTrials.gov</ExternalRef> website.</Para></SummarySection><SummarySection id="_158"><KeyPoint id="_159">Follow-up care may be needed.</KeyPoint><Para id="_158_md_33">As you go through treatment, you  will have follow-up tests or check-ups. Some tests that were done to <GlossaryTermRef href="CDR0000046450" dictionary="Cancer.gov" audience="Patient">diagnose</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045885" dictionary="Cancer.gov" audience="Patient">stage</GlossaryTermRef> the cancer may be repeated to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.</Para><Para id="_158_md_34">Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your condition has changed or if the cancer has recurred (come back). </Para></SummarySection></SummarySection><SummarySection id="_201"><Title>Treatment of Asymptomatic Chronic Lymphocytic Leukemia</Title><Para id="_225">For information about the treatment listed below, see the <SummaryRef href="CDR0000258005#_48" url="/types/leukemia/patient/cll-treatment-pdq">Treatment Option Overview</SummaryRef> section.</Para><Para id="_202">The treatment of <GlossaryTermRef href="CDR0000046520" dictionary="Cancer.gov" audience="Patient">asymptomatic</GlossaryTermRef> <GlossaryTermRef href="CDR0000044846" dictionary="Cancer.gov" audience="Patient">chronic lymphocytic leukemia</GlossaryTermRef> (CLL)  may  include <GlossaryTermRef href="CDR0000045942" dictionary="Cancer.gov" audience="Patient">watchful waiting</GlossaryTermRef>.</Para></SummarySection><SummarySection id="_204"><Title>Treatment of Symptomatic or Progressive Chronic Lymphocytic Leukemia</Title><Para id="_226">For information about the treatments listed below, see the <SummaryRef href="CDR0000258005#_48" url="/types/leukemia/patient/cll-treatment-pdq">Treatment Option Overview</SummaryRef>  section.</Para><Para id="_205"> The treatment of <GlossaryTermRef href="CDR0000044090" dictionary="Cancer.gov" audience="Patient">symptomatic</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045850" dictionary="Cancer.gov" audience="Patient">progressive</GlossaryTermRef> <GlossaryTermRef href="CDR0000044846" dictionary="Cancer.gov" audience="Patient">chronic lymphocytic leukemia</GlossaryTermRef> (CLL) may include the following:</Para><ItemizedList id="_206" Style="bullet">
     <ListItem><GlossaryTermRef href="CDR0000045942" dictionary="Cancer.gov" audience="Patient">Watchful waiting</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000270742" dictionary="Cancer.gov" audience="Patient">Targeted therapy</GlossaryTermRef> with any of the following drugs: <ItemizedList id="_235" Style="bullet"><ListItem>A <GlossaryTermRef href="CDR0000044833" dictionary="Cancer.gov" audience="Patient">tyrosine kinase inhibitor</GlossaryTermRef> (<GlossaryTermRef href="CDR0000791334" dictionary="Cancer.gov" audience="Patient">acalabrutinib</GlossaryTermRef>, <GlossaryTermRef href="CDR0000799967" dictionary="Cancer.gov" audience="Patient">zanubrutinib</GlossaryTermRef>, or   <GlossaryTermRef href="CDR0000754851" dictionary="Cancer.gov" audience="Patient">ibrutinib</GlossaryTermRef>).</ListItem><ListItem><GlossaryTermRef href="CDR0000780268" dictionary="Cancer.gov" audience="Patient">Venetoclax</GlossaryTermRef> with <GlossaryTermRef href="CDR0000754339" dictionary="Cancer.gov" audience="Patient">obinutuzumab</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045525" dictionary="Cancer.gov" audience="Patient">rituximab</GlossaryTermRef>.</ListItem></ItemizedList></ListItem><ListItem><GlossaryTermRef href="CDR0000045214" dictionary="Cancer.gov" audience="Patient">Chemotherapy</GlossaryTermRef> and rituximab.</ListItem><ListItem><GlossaryTermRef href="CDR0000045729" dictionary="Cancer.gov" audience="Patient">Immunotherapy</GlossaryTermRef> (<GlossaryTermRef href="CDR0000393761" dictionary="Cancer.gov" audience="Patient">lenalidomide</GlossaryTermRef>) with or without rituximab.</ListItem><ListItem>A <GlossaryTermRef href="CDR0000045961" dictionary="Cancer.gov" audience="Patient">clinical  trial</GlossaryTermRef> of <GlossaryTermRef href="CDR0000045622" dictionary="Cancer.gov" audience="Patient">bone marrow</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045828" dictionary="Cancer.gov" audience="Patient">peripheral blood stem cell</GlossaryTermRef> <GlossaryTermRef href="CDR0000046631" dictionary="Cancer.gov" audience="Patient">transplantation</GlossaryTermRef>.</ListItem></ItemizedList><Para id="_233">All of these treatments may be used for patients being treated for the first time and those who have been treated before. Because these treatments have not been compared in studies, it is not possible to know if one treatment is better than another. The choice of treatment is made based on test results, the patient's age and general health, and the desire to minimize <GlossaryTermRef href="CDR0000730423" dictionary="Cancer.gov" audience="Patient">short-term</GlossaryTermRef> and <GlossaryTermRef href="CDR0000693593" dictionary="Cancer.gov" audience="Patient">long-term side effects</GlossaryTermRef>.</Para></SummarySection><SummarySection id="_207"><Title>Treatment of Recurrent or Refractory Chronic Lymphocytic Leukemia</Title><Para id="_280">For information about the treatments listed below, see the <SummaryRef href="CDR0000258005#_48" url="/types/leukemia/patient/cll-treatment-pdq">Treatment Option Overview</SummaryRef> section.</Para><Para id="_208">The treatment of <GlossaryTermRef href="CDR0000045862" dictionary="Cancer.gov" audience="Patient">recurrent</GlossaryTermRef> or <GlossaryTermRef href="CDR0000350245" dictionary="Cancer.gov" audience="Patient">refractory</GlossaryTermRef> <GlossaryTermRef href="CDR0000044846" dictionary="Cancer.gov" audience="Patient">chronic lymphocytic leukemia</GlossaryTermRef> (CLL)  may include  therapies and <GlossaryTermRef href="CDR0000045961" dictionary="Cancer.gov" audience="Patient">clinical trials</GlossaryTermRef>.</Para><ItemizedList id="_274" Style="bullet"><ListItem><GlossaryTermRef href="CDR0000270742" dictionary="Cancer.gov" audience="Patient">Targeted therapy</GlossaryTermRef> with any of the following drugs:<ItemizedList id="_276" Style="bullet">
     <ListItem>A <GlossaryTermRef href="CDR0000044833" dictionary="Cancer.gov" audience="Patient">tyrosine kinase inhibitor</GlossaryTermRef> (<GlossaryTermRef href="CDR0000791334" dictionary="Cancer.gov" audience="Patient">acalabrutinib</GlossaryTermRef>, <GlossaryTermRef href="CDR0000799967" dictionary="Cancer.gov" audience="Patient">zanubrutinib</GlossaryTermRef>, or   <GlossaryTermRef href="CDR0000754851" dictionary="Cancer.gov" audience="Patient">ibrutinib</GlossaryTermRef>).</ListItem><ListItem><GlossaryTermRef href="CDR0000780268" dictionary="Cancer.gov" audience="Patient">Venetoclax</GlossaryTermRef> with or without <GlossaryTermRef href="CDR0000754339" dictionary="Cancer.gov" audience="Patient">obinutuzumab</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045525" dictionary="Cancer.gov" audience="Patient">rituximab</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000537262" dictionary="Cancer.gov" audience="Patient">Ofatumumab</GlossaryTermRef> with or without chemotherapy.</ListItem><ListItem><GlossaryTermRef href="CDR0000795008" dictionary="Cancer.gov" audience="Patient">Duvelisib</GlossaryTermRef>.</ListItem></ItemizedList></ListItem><ListItem><GlossaryTermRef href="CDR0000045214" dictionary="Cancer.gov" audience="Patient">Chemotherapy</GlossaryTermRef> with or without rituximab.</ListItem><ListItem><GlossaryTermRef href="CDR0000045729" dictionary="Cancer.gov" audience="Patient">Immunotherapy</GlossaryTermRef> (<GlossaryTermRef href="CDR0000393761" dictionary="Cancer.gov" audience="Patient">lenalidomide</GlossaryTermRef>) with or without rituximab.</ListItem><ListItem><GlossaryTermRef href="CDR0000045622" dictionary="Cancer.gov" audience="Patient">Bone marrow</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045828" dictionary="Cancer.gov" audience="Patient">peripheral blood stem cell</GlossaryTermRef> <GlossaryTermRef href="CDR0000046631" dictionary="Cancer.gov" audience="Patient">transplantation</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000044971" dictionary="Cancer.gov" audience="Patient">Radiation therapy</GlossaryTermRef> as <GlossaryTermRef href="CDR0000045815" dictionary="Cancer.gov" audience="Patient">palliative treatment</GlossaryTermRef> to relieve <GlossaryTermRef href="CDR0000045022" dictionary="Cancer.gov" audience="Patient">symptoms</GlossaryTermRef> and improve <GlossaryTermRef href="CDR0000045417" dictionary="Cancer.gov" audience="Patient">quality of life</GlossaryTermRef>.</ListItem><ListItem>A <GlossaryTermRef href="CDR0000045961" dictionary="Cancer.gov" audience="Patient">clinical trial</GlossaryTermRef> of <GlossaryTermRef href="CDR0000771302" dictionary="Cancer.gov" audience="Patient">CAR T-cell therapy</GlossaryTermRef>.</ListItem></ItemizedList></SummarySection><SummarySection id="_145"><Title>To Learn More About Chronic Lymphocytic Leukemia</Title><Para id="_146">For more information from the <GlossaryTermRef href="CDR0000044266" dictionary="Cancer.gov" audience="Patient">National Cancer Institute</GlossaryTermRef> about  <GlossaryTermRef href="CDR0000044846" dictionary="Cancer.gov" audience="Patient">chronic lymphocytic leukemia</GlossaryTermRef>, see:</Para><ItemizedList id="_170" Style="bullet"><ListItem><ExternalRef xref="https://www.cancer.gov/types/leukemia">Leukemia Home Page</ExternalRef> </ListItem><ListItem><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/drugs/leukemia">Drugs Approved for Chronic Lymphocytic Leukemia</ExternalRef></ListItem><ListItem><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies">Targeted Therapy to Treat Cancer</ExternalRef></ListItem><ListItem><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/immunotherapy">Immunotherapy to Treat Cancer</ExternalRef></ListItem></ItemizedList><Para id="_145_md_40">For general cancer information and other resources from the National Cancer Institute, visit:</Para><ItemizedList id="_145_md_41" Style="bullet"><ListItem><ExternalRef xref="https://www.cancer.gov/about-cancer">About Cancer</ExternalRef></ListItem><ListItem><ExternalRef xref="https://www.cancer.gov/about-cancer/diagnosis-staging/staging">Cancer Staging</ExternalRef></ListItem><ListItem><ExternalRef xref="https://www.cancer.gov/publications/patient-education/chemo-and-you">Chemotherapy and You: Support for People With Cancer</ExternalRef></ListItem><ListItem><ExternalRef xref="https://www.cancer.gov/publications/patient-education/radiation-therapy-and-you">Radiation Therapy and You: Support for People With Cancer</ExternalRef></ListItem><ListItem><ExternalRef xref="https://www.cancer.gov/about-cancer/coping">Coping with Cancer</ExternalRef></ListItem><ListItem><ExternalRef xref="https://www.cancer.gov/about-cancer/coping/questions">Questions to Ask Your Doctor about Cancer</ExternalRef></ListItem><ListItem><ExternalRef xref="https://cancercontrol.cancer.gov/ocs/resources/survivors.html">For Survivors, Caregivers, and Advocates</ExternalRef></ListItem></ItemizedList></SummarySection><SummarySection id="_AboutThis_1"><Title>About This PDQ Summary</Title><SummarySection id="_AboutThis_2"><Title>About PDQ</Title><Para id="_AboutThis_3">Physician Data Query (PDQ) is the National Cancer Institute's (NCI's) comprehensive cancer information database. The PDQ database contains summaries of the latest published information on cancer prevention, detection, genetics, treatment, supportive care, and complementary and alternative medicine. Most summaries come in two versions. The health professional versions have detailed information written in technical language. The patient versions are written in easy-to-understand, nontechnical language. Both versions have cancer information that is accurate and up to date and most versions are also available in <ExternalRef xref="https://www.cancer.gov/espanol/publicaciones/pdq">Spanish</ExternalRef>.</Para><Para id="_AboutThis_4">PDQ is a service of the NCI. The NCI is part of the National Institutes of Health (NIH). NIH is the federal government’s center of biomedical research.  The PDQ summaries are based on an independent review of the medical literature. They are not policy statements of the NCI or the NIH.</Para></SummarySection><SummarySection id="_AboutThis_5"><Title>Purpose of This Summary</Title><Para id="_AboutThis_6">This PDQ cancer information summary has current information about the treatment of chronic lymphocytic leukemia.  It is meant to inform and help patients, families, and caregivers. It does not give formal guidelines or recommendations for making decisions about health care.</Para></SummarySection><SummarySection id="_AboutThis_7"><Title>Reviewers and Updates</Title><Para id="_AboutThis_8">Editorial Boards write the PDQ cancer information summaries and keep them up to date. These Boards are made up of experts in cancer treatment and other specialties related to cancer. The summaries are reviewed regularly and changes are made when there is new information. The date on each summary ("Updated") is the date of the most recent change.
</Para><Para id="_AboutThis_9">The information in this patient summary was taken from the health professional version, which is reviewed regularly and updated as needed, by the <ExternalRef xref="https://www.cancer.gov/publications/pdq/editorial-boards/adult-treatment">PDQ Adult Treatment Editorial Board</ExternalRef>.
</Para></SummarySection><SummarySection id="_AboutThis_10"><Title>Clinical Trial Information</Title><Para id="_AboutThis_11">A clinical trial is a study to answer a scientific question, such as whether one treatment is better than another. Trials are based on past studies and what has been learned in the laboratory. Each trial answers certain scientific questions in order to find new and better ways to help cancer patients. During treatment clinical trials, information is collected about the effects of a new treatment and how well it works. If a clinical trial shows that a new treatment is better than one currently being used, the new treatment may become "standard." Patients may want to think about taking part in a clinical trial. Some clinical trials are open only to patients who have not started treatment.
</Para><Para id="_AboutThis_12">Clinical trials can be found online at <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials">NCI's website</ExternalRef>. For more information, call the <ExternalRef xref="https://www.cancer.gov/contact/contact-center">Cancer Information Service</ExternalRef> (CIS), NCI's contact center, at 1-800-4-CANCER (1-800-422-6237).
</Para></SummarySection><SummarySection id="_AboutThis_13"><Title>Permission to Use This Summary</Title><Para id="_AboutThis_14">PDQ is a registered trademark. The content of PDQ documents can be used freely as text. It cannot be identified as an NCI PDQ cancer information summary unless the whole summary is shown and it is updated regularly. However, a user would be allowed to write a sentence such as “NCI’s PDQ cancer information summary about breast cancer prevention states the risks in the following way: [include excerpt from the summary].”
</Para><Para id="_AboutThis_15">The best way to cite this PDQ summary is:</Para><Para id="_AboutThis_21">PDQ® Adult Treatment Editorial Board. PDQ Chronic Lymphocytic Leukemia Treatment. Bethesda, MD: National Cancer Institute. Updated  &lt;MM/DD/YYYY&gt;. Available at: <ExternalRef xref="https://www.cancer.gov/types/leukemia/patient/cll-treatment-pdq">https://www.cancer.gov/types/leukemia/patient/cll-treatment-pdq</ExternalRef>.  Accessed &lt;MM/DD/YYYY&gt;. [PMID: 26389485]</Para><Para id="_AboutThis_16">Images in this summary are used with permission of the author(s), artist, and/or publisher for use in the PDQ summaries only. If you want to use an image from a PDQ summary and you are not using the whole summary, you must get permission from the owner. It cannot be given by the National Cancer Institute. Information about using the images in this summary, along with many other images related to cancer can be found in <ExternalRef xref="https://visualsonline.cancer.gov/">Visuals Online</ExternalRef>. Visuals Online is a collection of more than 3,000 scientific images.
</Para></SummarySection><SummarySection id="_AboutThis_17"><Title>Disclaimer</Title><Para id="_AboutThis_18">The information in these summaries should not be used to make decisions about insurance reimbursement. More information on insurance coverage is available on Cancer.gov on the <ExternalRef xref="https://www.cancer.gov/about-cancer/managing-care">Managing Cancer Care</ExternalRef> page.</Para></SummarySection><SummarySection id="_AboutThis_19"><Title>Contact Us</Title><Para id="_AboutThis_20">More information about contacting us or receiving help with the Cancer.gov website can be found on our <ExternalRef xref="https://www.cancer.gov/contact">Contact Us for Help</ExternalRef> page. Questions can also be submitted to Cancer.gov through the website’s <ExternalRef xref="https://www.cancer.gov/contact/email-us">E-mail Us</ExternalRef>.</Para></SummarySection></SummarySection><PatientVersionOf ref="CDR0000062856"/><DateLastModified>2024-10-15</DateLastModified></Summary>
